Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova announced preliminary results for the unipolar patient cohort in its RECOVER clinical study of VNS Therapy for treatment-resistant depression. The primary endpoint (PE) did not achieve statistical significance due to an unforeseen strong response in the sham group. However, select secondary endpoints showed statistically significant and clinically meaningful benefits, with no safety concerns reported. The company plans to publish detailed data in peer-reviewed journals by Q4 2024. The RECOVER study's bipolar patient cohort continues, and discussions with U.S. Medicare and Medicaid Services for VNS Therapy coverage are ongoing.
LivaNova (Nasdaq: LIVN), a leading medical technology company, announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Goldman Sachs Healthcare Conference.
The event will take place in Miami, Florida, on June 10 at 1:20 p.m. Eastern Time. A webcast will be available for those who register on the LivaNova website.
The webcast will also be accessible as a replay for 90 days following the live presentation.
LivaNova PLC (Nasdaq: LIVN) reported strong first-quarter 2024 results with revenue of $294.9 million, a 12.0% increase, and adjusted diluted earnings per share of $0.73. The company raised its full-year 2024 revenue guidance to grow between 6-7% on a constant-currency basis. LivaNova achieved positive trial outcomes in the OSPREY clinical study for obstructive sleep apnea. The company closed a private offering of $345.0 million convertible senior notes due 2029 and repurchased $230.0 million exchangeable senior notes due 2025.
LivaNova PLC announced the appointment of Ahmet Tezel, Ph.D., as Chief Innovation Officer, effective May 13, 2024. Tezel will lead the development of new technologies leveraging his 20+ years of experience in research and development. His role will enhance the Company's innovation capabilities in neurological and cardiac health.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
